Core Insights - NeuroBo Pharmaceuticals has completed enrollment for the single ascending dose (SAD) Part 1 of its Phase 1 clinical trial for DA-1726, a dual agonist for obesity treatment, with 45 participants randomized into five cohorts [1][2] - The company reported no significant issues during the SAD study, allowing for an accelerated start to the multiple ascending dose (MAD) Part 2, with top-line data expected in Q3 2024 and Q1 2025 respectively [1][2] - DA-1726 has shown superior weight loss in pre-clinical studies compared to semaglutide and similar weight reduction while allowing for greater food intake compared to tirzepatide [2][5] Company Overview - NeuroBo Pharmaceuticals is focused on transforming cardiometabolic diseases and is developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [7] - DA-1726 acts as a dual agonist of GLP-1 and glucagon receptors, leading to weight loss through appetite reduction and increased energy expenditure [5][6] - The company aims to provide differentiated therapies in the cardiometabolic space, with DA-1726 potentially becoming a best-in-class obesity drug due to its tolerability profile [2][5] Clinical Trial Details - The Phase 1 trial is designed as a randomized, placebo-controlled, double-blind study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DA-1726 [3] - The primary endpoint focuses on monitoring adverse events, while secondary endpoints include serum concentrations and metabolic parameters [3] - The MAD study is expected to enroll approximately 36 participants, with the first patient dosed ahead of schedule [2][3]
NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity